These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350 [TBL] [Abstract][Full Text] [Related]
9. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
10. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
13. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743 [TBL] [Abstract][Full Text] [Related]
14. Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis. De Dosso S; Treglia G; Pascale M; Tamburello A; Santhanam P; Kroiss AS; Pereira Mestre R; Saletti P; Giovanella L Endocrine; 2019 Jun; 64(3):456-468. PubMed ID: 31004334 [TBL] [Abstract][Full Text] [Related]
15. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333 [TBL] [Abstract][Full Text] [Related]
16. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma. Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126 [TBL] [Abstract][Full Text] [Related]
17. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422 [TBL] [Abstract][Full Text] [Related]
18. Molecular imaging for neuroendocrine tumours. Antwi K; Nicolas G; Wild D; Christ E Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831 [TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
20. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience. Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]